Kailera Therapeutics, Inc. — Investor Relations & Filings

Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing the next era of obesity care. The company develops a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Its pipeline, designed with an obesity-first focus, includes four clinical-stage product candidates that leverage multiple GLP-1-based mechanisms of action and routes of administration. Kailera aims to provide diverse treatment options for individuals living with obesity, addressing critical needs within the current therapeutic landscape. Its lead program is a dual-action gut hormone receptor agonist.